eMedicine Specialties > Ophthalmology > Lid

Entropion: Treatment & Medication

Author: Christopher DeBacker, MD, Volunteer Faculty, Department of Ophthalmology, California Pacific Medical Center; Consulting Staff, Ophthalmic Medical Associates
Coauthor(s): Robert M Dryden, MD, FACS, Clinical Professor, Department of Ophthalmology, University of Arizona School of Medicine
Contributor Information and Disclosures

Updated: Oct 30, 2009

Treatment

Medical Care

  • Medical therapy may be warranted for patients who decline surgery and as a temporizing maneuver in patients who may improve spontaneously.3
  • Ocular lubrication and tear preparations are helpful for protecting the ocular surface and also may break the cycle in patients with spastic entropion due to dry eye syndrome.
  • Eyelid hygiene, antibiotics, and corticosteroids are useful for the treatment of blepharitis, which may cause spastic entropion.
  • Small amounts of botulinum toxin (BOTOX®) (approximately 5 U) are quite effective for the treatment of spastic entropion by weakening the pretarsal orbicularis oculi muscle.
  • Patients with cicatricial entropion secondary to ocular cicatricial pemphigoid may benefit from systemic chemotherapy, usually dapsone.

Surgical Care

Multiple surgical procedures have been described for the management of entropion.4,5,6 The procedure chosen must be appropriate for the class of entropion being treated.

Involutional entropion. Correction of entropion ...

Involutional entropion. Correction of entropion with eyelid retractor reattachment and lateral canthopexy.

Involutional entropion. Correction of entropion ...

Involutional entropion. Correction of entropion with eyelid retractor reattachment and lateral canthopexy.


The most common procedures utilized in the management are as follows:

  • Temporizing Quickert-Rathbun sutures7
    • They are effective for many cases of spastic entropion, as well as for some cases of involutional entropion in which the patient refuses or is medically unable to undergo more definitive procedures.
    • Full-thickness eyelid sutures (usually gut suture) from the inferior fornix anteriorly toward the lashes are used to torque the eyelid margin away from the globe. Tissue reaction to the gut suture helps to create a cicatrix in the eyelid that maintains the eyelid in the everted position.
  • Repair of involutional entropion
    • It may require repair of the horizontal laxity via medial and/or lateral canthal tightening.
    • The vertical component is best repaired by vertically shortening or reattaching the lower eyelid retractors to the inferior border of the tarsus via a lower eyelid transcutaneous approach.
    • A small amount of the pretarsal orbicularis oculi can be resected concurrently to prevent further overriding of the tarsus.
  • Procedures for the repair of cicatricial entropion
    • They will depend on the degree of scarring and entropion, the etiology of the cicatricial changes, and the status of the tarsal plate.
    • Mild cases can be treated with a transverse blepharotomy with marginal rotation (Wies procedure).
    • More extensive scarring may require oral mucous membrane (eg, buccal mucosa) or cadaveric dermis (eg, Alloderm) grafts.
    • It is important that the inflammatory process is in a quiescent state in OCP patients prior to any procedure that violates the conjunctiva. Any manipulation of the conjunctiva in these patients may cause a recurrence of inflammation with failure of the procedure.
    • Assess the status of the tarsal plate in all cases of cicatricial entropion. If it is distorted, place a facsimile of tarsus following excision of the distorted portions of the tarsal plate. Materials such as autologous tarsus, hard palate grafts, and chondromucosal grafts have been used successfully for this purpose.

Consultations

Consultation with an internist or a hematologist is recommended for OCP patients requiring immunosuppressive medications, as well as for systemic evaluation to rule out other autoimmune diseases.

Medication

Topical, local, and systemic medications may be useful in the management of various forms of entropion.

Ocular lubricants

Topical ocular lubricants may be necessary to increase patient comfort and to diminish abrasive conjunctivopathy and keratopathy.


Artificial tears

Preservative-free artificial tears are preferred to avoid preservative-associated ocular reactions.

Adult

1-2 gtt into eye(s) prn

Pediatric

Administer as in adults

Pregnancy

A - Fetal risk not revealed in controlled studies in humans

Precautions

Hyperemia, photophobia, stickiness of eyelashes, ocular discomfort or irritation may occur

Immunosuppressive agents

These medications have been shown to effectively diminish the autoinflammatory reaction associated with ocular cicatricial pemphigoid.


Dapsone (Avlosulfon)

Bactericidal and bacteriostatic against mycobacteria; mechanism of action is similar to that of sulfonamides where competitive antagonists of PABA prevent formation of folic acid, inhibiting bacterial growth.

Adult

100 mg/d PO

Pediatric

Not established

May inhibit anti-inflammatory effects of clofazimine; hematologic reactions may increase with folic acid antagonists, eg, pyrimethamine (monitor for agranulocytosis during the second and third months of therapy); probenecid increases dapsone toxicity; trimethoprim with dapsone may increase toxicity of both drugs; due to increased in renal clearance, dapsone levels may significantly decrease when administered concurrently with rifampin

Documented hypersensitivity; known G-6-PD deficiency

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Perform weekly blood counts (first month); then perform WBC counts monthly (6 mo); then semi-annually; discontinue if significant reduction in platelets, leukocytes, or hematopoiesis is seen
Caution in methemoglobin reductase deficiency, G-6-PD deficiency (patients receiving >200 mg/d), or hemoglobin M due to high risk for hemolysis and Heinz body formation; caution in patients exposed to other agents or conditions (eg, infection, diabetic ketosis) capable of producing hemolysis
Peripheral neuropathy can occur (rare)
Phototoxicity may occur when exposed to UV light

Neuromuscular transmission blocking agents

Weakening or paralyzing the orbicularis muscle of the lower eyelid helps in preventing the inturning of the lower eyelid in cases of spastic and involutional entropion.


Botulinum toxin type A (BOTOX®)

Temporarily paralyzes the muscles by inhibiting acetylcholine release. Duration of effectiveness usually is 3-4 mo.

Adult

5-10 U injected into orbicularis muscle

Pediatric

Not established

Aminoglycosides or drugs that interfere with neuromuscular transmission may potentiate effects of botulinum toxin

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Injection should not be too superficial such that the orbicularis muscle is not affected or too deeply such that the inferior oblique muscle is weakened; do not exceed recommended dosages and frequencies of administration; presence of antibodies to botulinum toxin type A may reduce effects of therapy

More on Entropion

Overview: Entropion
Differential Diagnoses & Workup: Entropion
Treatment & Medication: Entropion
Follow-up: Entropion
Multimedia: Entropion
References
Further Reading

References

  1. Awan MA, Chadha V, Gonzalez P, Diaper CJ, Cauchi P, Kemp EG. Small tarsal plates causing recurrent lower lid entropion in a young adult. Eye. Feb 6 2009;[Medline].

  2. Pasco NY, Kikkawa DO, Korn BS, Punja KG, Jones MC. Facial nerve paralysis: an unrecognized cause of lower eyelid entropion in the pediatric population. Ophthal Plast Reconstr Surg. Mar-Apr 2007;23(2):126-9. [Medline].

  3. Maycock NJ, Sahu DN, Mota PM, Gaston H, Hodgkins PR. Conservative management of upper eyelid entropion. J Pediatr Ophthalmol Strabismus. Nov-Dec 2008;45(6):377-8. [Medline].

  4. Gu J, Wang Z, Sun M, Yuan J, Chen J. Posterior lamellar eyelid reconstruction with acellular dermis allograft in severe cicatricial entropion. Ann Plast Surg. Mar 2009;62(3):268-74. [Medline].

  5. Swamy BN, Benger R, Taylor S. Cicatricial entropion repair with hard palate mucous membrane graft: surgical technique and outcomes. Clin Experiment Ophthalmol. May 2008;36(4):348-52. [Medline].

  6. Hintschich C. Correction of entropion and ectropion. Dev Ophthalmol. 2008;41:85-102. [Medline].

  7. Ho SF, Pherwani A, Elsherbiny SM, Reuser T. Lateral tarsal strip and quickert sutures for lower eyelid entropion. Ophthal Plast Reconstr Surg. Sep 2005;21(5):345-8. [Medline].

  8. Bartley GB, Kay PP. Posterior lamellar eyelid reconstruction with a hard palate mucosal graft. Am J Ophthalmol. Jun 15 1989;107(6):609-12. [Medline].

  9. Cheung D, Sandramouli S. Consecutive ectropion after the Wies procedure. Ophthal Plast Reconstr Surg. Jan 2004;20(1):64-8. [Medline].

  10. Christiansen G, Mohney BG, Baratz KH, Bradley EA. Botulinum toxin for the treatment of congenital entropion. Am J Ophthalmol. Jul 2004;138(1):153-5. [Medline].

  11. Dortzbach RK, McGetrick JJ. Involutional entropion of the lower eyelid. Ophthalmic Plast Reconstr Surg. 1983;2:257-267.

  12. Khan SJ, Meyer DR. Transconjunctival lower eyelid involutional entropion repair: long-term follow-up and efficacy. Ophthalmology. Nov 2002;109(11):2112-7. [Medline].

  13. McCord CD Jr, Chen WP. Tarsal polishing and mucous membrane grafting for cicatricial entropion, trichiasis and epidermalization. Ophthalmic Surg. Dec 1983;14(12):1021-5. [Medline].

  14. Millman AL, Katzen LB, Putterman AM. Cicatricial entropion: an analysis of its treatment with transverse blepharotomy and marginal rotation. Ophthalmic Surg. Aug 1989;20(8):575-9. [Medline].

  15. Quickert MH, Rathbun E. Suture repair of entropion. Arch Ophthalmol. Mar 1971;85(3):304-5. [Medline].

Keywords

entropion, involutional entropion, cicatricial entropion, acute spastic entropion, congenital entropion, eyelid entropion, eyelid inversion, eyelid margin inversion, ocular irritation, eyelid retraction, corneal abrasions

Contributor Information and Disclosures

Author

Christopher DeBacker, MD, Volunteer Faculty, Department of Ophthalmology, California Pacific Medical Center; Consulting Staff, Ophthalmic Medical Associates
Christopher DeBacker, MD is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Ophthalmology, American Society of Ophthalmic Plastic and Reconstructive Surgery, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Coauthor(s)

Robert M Dryden, MD, FACS, Clinical Professor, Department of Ophthalmology, University of Arizona School of Medicine
Robert M Dryden, MD, FACS is a member of the following medical societies: Alpha Omega Alpha, American Academy of Cosmetic Surgery, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Ophthalmology, American College of Surgeons, American Society of Ophthalmic Plastic and Reconstructive Surgery, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Medical Editor

Ron W Pelton, MD, PhD, Private Practice, Colorado Springs, Colorado
Ron W Pelton, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Ophthalmic Plastic and Reconstructive Surgery, Colorado Medical Society, Utah Medical Association, and Wilderness Medical Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Managing Editor

Mark T Duffy, MD, PhD, Consulting Staff, Division of Oculoplastic, Orbito-facial, Lacrimal and Reconstructive Surgery, Green Bay Eye Clinic, BayCare Clinic; Medical Director, Advanced Cosmetic Solutions, A BayCare Clinic
Mark T Duffy, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Ophthalmic Plastic and Reconstructive Surgery, Sigma Xi, and Society for Neuroscience
Disclosure: Allergan - Botox Cosmetic Consulting fee Consulting; Quest medical - lacrimal balloons Honoraria Speaking and teaching; Ortho-Neutrogenia Consulting fee Consulting

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.